Skip to main content
. 2020 Dec 10;10:593989. doi: 10.3389/fonc.2020.593989

Figure 3.

Figure 3

Validation of RE neoantigen in ovarian tumor cohort. (A) RE neoantigen identified by PREP in 14 ovarian tumor sample. (B) RE neoantigen identified in the OvCa84 tumor sample originating from gene OSBPL9 was predicted by PREP and validated by mass spectrometry in the immunopeptidome.